The results revealed a significant decrease in both FGF1 mRNA and protein levels, suggesting a potential involvement of FGF1 dysregulation in the pathogenesis of MASLD (Fig. 2E, F). This evidence concerns the gene FGF1 and metabolic dysfunction-associated steatotic liver disease.